Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

A potential explanation is the observation that serum BAFF levels are elevated after treatment with rituximab and may lead to disease flare by facilitating maturation of and re-population with ...

The FDA has approved tafasitamab in combination with lenalidomide and rituximab for adults with relapsed/refractory ...